Literature DB >> 16212635

Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression.

E Steve Woodle1, Rita R Alloway, Joseph F Buell, J Wesley Alexander, Rino Munda, Prabir Roy-Chaudhury, M Roy First, Michael Cardi, Jennifer Trofe.   

Abstract

The purpose of this study was to define risk factors for acute rejection with early corticosteroid withdrawal (CSWD; within 7 days posttransplant) in renal transplantation. Data from prospective, IRB-approved early CSWD trials were analyzed. Overall acute rejection rate in 308 patients was 17.1%. Acute rejection rates and observed risks (OR) in patients with individual risk factors were: repeat transplants 38.6%; current PRA >25%; 29.4%; African Americans 23.5%; delayed graft function (DGF) 26.1%; HLA DR mismatches >0 17.9%; female gender 19.7%; Thymoglobulin induction 15.3%; type 1 diabetes 30.8%; type 2 diabetes 11.1%; deceased donor recipients 21%; and living donor recipients 14%. Logistic regression analysis provided the following risks (OR) for acute rejection: repeat transplant 2.51; current PRA > 25% 1.53; African Americans 1.47; DGF 1.58; HLA DR mismatches > 0 1.61; female gender 1.43; Thymoglobulin induction 0.61; type 1 diabetes 2.23, type 2 diabetes 0.5, deceased donor recipients 1.11, and living donor recipients 0.9. Risk factors for acute rejection under early corticosteroid withdrawal are similar to those previously defined under chronic corticosteroid therapy. These observations provide implications for future CSWD trials including: use of T cell depleting antibody induction therapy (thymoglobulin) to reduce acute rejection risk, 2) enrollment stratification for high risk groups, and 3) modified immunosuppression for high risk groups.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16212635     DOI: 10.1111/j.1600-6143.2005.01090.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  18 in total

1.  Recommendations for the assessment and reporting of multivariable logistic regression in transplantation literature.

Authors:  A C Kalil; J Mattei; D F Florescu; J Sun; R S Kalil
Journal:  Am J Transplant       Date:  2010-07       Impact factor: 8.086

2.  Risk factors for delayed graft function and their impact on graft outcomes in live donor kidney transplantation.

Authors:  Shivashankar Damodaran; Brenna Bullock; Obi Ekwenna; Mehdi Nayebpour; Naoru Koizumi; Puneet Sindhwani; Jorge Ortiz
Journal:  Int Urol Nephrol       Date:  2021-01-04       Impact factor: 2.370

3.  Early steroid withdrawal in repeat kidney transplantation.

Authors:  Muhammad A Mujtaba; Tim E Taber; William C Goggins; Muhammad S Yaqub; Dennis P Mishler; Martin L Milgrom; Jonathan A Fridell; Andrew Lobashevsky; John A Powelson; Asif A Sharfuddin
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-04       Impact factor: 8.237

Review 4.  Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy?

Authors:  Fu L Luan; Diane E Steffick; Akinlolu O Ojo
Journal:  Kidney Int       Date:  2009-07-22       Impact factor: 10.612

5.  Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits.

Authors:  L Li; A Chang; M Naesens; N Kambham; J Waskerwitz; J Martin; C Wong; S Alexander; P Grimm; W Concepcion; O Salvatierra; M M Sarwal
Journal:  Am J Transplant       Date:  2009-05-13       Impact factor: 8.086

Review 6.  Renal transplantation with early steroid withdrawal.

Authors:  Jeffrey Schiff; Edward H Cole
Journal:  Pediatr Nephrol       Date:  2008-06-06       Impact factor: 3.714

Review 7.  Renal transplantation in high-risk patients.

Authors:  Nicole A Weimert; Rita R Alloway
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression.

Authors:  F L Luan; D E Steffick; C Gadegbeku; S P Norman; R Wolfe; A O Ojo
Journal:  Am J Transplant       Date:  2008-10-24       Impact factor: 8.086

Review 9.  Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result.

Authors:  Titte R Srinivas; Herwig-Ulf Meier-Kriesche
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

10.  Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis.

Authors:  Mingjie Shao; Tingting Tian; Xinyan Zhu; Yingzi Ming; Yasuko Iwakiri; Shaojun Ye; Qifa Ye
Journal:  Oncotarget       Date:  2017-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.